| OCR Text |
Show 52 Figure 3.5. (A) Eticlopride pretreatment attenuates METH-induced loss of VMAT2 and increased GFAF> METH-treatment. immunoreactivity (8), Rats received four s.c.: 2-h intervals) or saline vehicle (1 sacrificed 72 h later. as assessed 72 h following injections of METH (7.5 mg/kg/injection; ml/kg/injection; s.c.; 2-h intervals) and were Thirty min prior to each injection, rats were pretreated with eticlopride (0.6 mglkg/injection; i.p.) or saline vehide (1 ml/kg/injection; i.p.). Columns represent the means and vertical lines 1 SEM determinations in 6-10 rats. *, values different from saline-treated controls (p s 0.05). t. values different from saline/METH-treated group (p s 0.05). |
